andy,i typed mesenchymal precursor cells into pubmed and turned up 1052 results.
Msb is a work in progress ,its difficult to make assumptions based on trials involving 100 or so patients hence the need for phase 3 trials (1500 patients ).
My understanding is that there will be publications and there will be peer reviews.
I believe that the share price accurately reflects these processes and that's why the company is values 1.6 bil and not 20 bil.
i value your thoughts and yet my view is that there is enough on the table now to warrant a punt on the prof and his team
inFact ,and for the record , "I'M ALL IN !!".
GO U GOOD THING !!!!!
(FELLOW MESOPHILES PLEASE DYOR!!!!!!)
GO THE SWANS!!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
0.015(0.93%) |
Mkt cap ! $2.082B | |||
| Open | High | Low | Value | Volume |
| $1.63 | $1.67 | $1.61 | $6.975M | 4.265M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 707 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.64 | 7320 | 2 |
View Market Depth
| Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |